Companies currently with Covid-19 Vaccine Candidates in Phase I clinical trials

by goodDayM

Source: The COVID-19 vaccine development landscape (nature.com)

Developer Candidate Vaccine Characteristics Status
Moderna mRNA-1273 LNP-encapsulated mRNA vaccine encoding S protein Phase I (NCT04283461)
CanSino Biologicals Ad5-nCoV Adenovirus type 5 vector that expresses S protein Phase I (NCT04313127)
Inovio Pharmaceuticals INO-4800 DNA plasmid encoding S protein delivered by electroporation Phase I (NCT04336410)
Shenzhen Geno-Immune Medical Institute LV-SMENP-DC DCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific CTLs Phase I (NCT04276896)
Shenzhen Geno-Immune Medical Institute Pathogen-specific aAPC aAPCs modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins Phase I (NCT04299724)

There are dozens of other vaccine candidates in development:

Of the confirmed active vaccine candidates, 56 (72%) are being developed by private/industry developers, with the remaining 22 (28%) of projects being led by academic, public sector and other non-profit organizations. Although a number of large multinational vaccine developers (such as Janssen, Sanofi, Pfizer and GlaxoSmithKine) have engaged in COVID-19 vaccine development, many of the lead developers are small and/or inexperienced in large-scale vaccine manufacture.

 

Disclaimer: This information is only for educational purposes. Do not make any investment decisions based on the information in this article. Do you own due diligence.